GLP-1 medications show varied impacts on socioeconomic status and kidney health

Recent studies regarding GLP-1 receptor agonists have provided new insights into the clinical and socioeconomic impacts of these diabetes medications.

An economic analysis by researchers at the University of Chicago Harris School of Public Policy, published via the National Bureau of Economic Research, examined federal survey data from 2012 to 2023. The study followed individuals with diabetes to determine if starting GLP-1 medications led to changes in employment, marital status, mental health, or self-rated health. The findings indicated no measurable change in these personal and professional circumstances compared to the patients' own status prior to treatment. The researchers noted that while the drugs are effective for blood sugar control and weight loss, these physical changes did not translate into shifts in social or economic functioning within the observed timeframe.

In a separate clinical study published in the American Journal of Kidney Diseases, researchers investigated the renal benefits of different GLP-1 medications. Using administrative claims data from the OptumLabs Data Warehouse and Medicare, the study compared semaglutide with dulaglutide, exenatide, and liraglutide among adults with type 2 diabetes. While no significant differences were found regarding the primary kidney outcome—incident chronic kidney disease (CKD) stages 3–4 and kidney failure—the initiation of semaglutide was associated with a lower risk of a secondary composite outcome, which included all-cause mortality.